The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers
Journal of Psychopharmacology – May 01, 2000
Source: OpenAlex
Summary
Pretreatment with citalopram significantly mitigated the cardiovascular and vegetative effects of MDMA in a study involving 16 healthy volunteers. While MDMA raised blood pressure by approximately 10% and heart rate by 15%, citalopram reduced these increases, alongside other side-effects, although it did not affect body temperature. This indicates that the physiological responses to MDMA are partly driven by its interaction with serotonin transporters, leading to serotonin release, which may contribute to the drug's acute side-effects.
Abstract
MDMA (3, 4-methylenedioxymethamphetamine) or ‘Ecstasy’ is a widely used recreational drug that produces a state of heightened mood but also cardiovascular and vegetative side-effects. In animals, MDMA releases serotonin and, to a lesser extent, dopamine and norepinephrine. The release of serotonin can be blocked by serotonin uptake inhibitors such as citalopram. It is unknown to what extent this mechanism is also responsible for the physiological side-effects of MDMA seen in humans. We investigated the effect of citalopram pretreatment (40 mg i.v.) on vegetative and cardiovascular effects of MDMA (1.5 mg/kg p.o.) in a double-blind placebo-controlled study in 16 healthy volunteers. MDMA moderately increased blood pressure and heart rate, slightly elevated body temperature and produced a broad range of acute and shortterm side-effects. Citalopram reduced all these MDMA-induced physiological changes except for body temperature. These findings suggest that physiological effects of MDMA in humans are partially due to an interaction of MDMA with the serotonin carrier and a subsequent release of serotonin.